If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Journal of Paediatrics and Child HealthVolume 41 Issue 11, Pages 558 - 560 Published Online: 3 Nov 2005 Journal compilation © 2010 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Abstract | References | Full Text: HTML, PDF (Size: 53K) | Related Articles | Citation Tracking Annotation Ethical issues in the relationships with industry: An ongoing challenge. New Guidelines open for public comment Copyright 2005 Division of Paediatrics (The Royal Australasian College of Physicians) KEYWORDS conflicts of interest • ethics • pharmaceutical industry ABSTRACTAbstract: Interactions between medical practitioners and industry have a profound impact on medical decision-making. It is important to establish clear guidelines to ensure that the values of clinical care, the welfare of society and science prevail over commercial imperatives and monetary values, The Royal Australasian Collage of Physicians has revised its Guidelines for the relationships involving medical practitioners and industry to provide practical assistance to health care professionals in the understanding and management of thier interactions with industry. The Guidelines are advisory but provide argument and references to support their conclusions. They outline a practical approach to the management of dualities and conflicts of interests. Among other things, they recommend that gifts should be rejected, including those of small value and etertainment expenses. They argue that industry sponsorship to attend meetings should be restricted to cases where formal contributions are being made, that drug samples should not be accepted from pharmaceutical representatives and that endorsements of specific products and "advertorials" should be avoided. They propose that clinicians should not actively recruit their own patients into studies in which they are investigators and that it should be a condition of agreement to participate by researchers and approval by ethics committees that there is a commitment to make publicly available all results potentially relevant to clinical practice. The Guidelines are intended to reflect changing community attitudes and will continue to be revised frome time to time. Accepted for publication 5 July 2005. |